Business
Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023.
Mike Blake | Reuters
Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to file for approval of the drug globally.
The treatment is inching closer to becoming a new, needle-free alternative in the highly lucrative market for weight loss and diabetes drugs called GLP-1s. More convenient pills could boost supply for the treatments and make them easier to access than the pricey weekly injections currently dominating the space. The Eli Lilly pill also would not come with dietary restrictions, in contrast to a similar oral treatment from chief rival Novo Nordisk.
Eli Lilly shares climbed more than 4% Tuesday.
The highest dose of the pill, orforglipron, helped patients lose 10.5% of their weight, or 22.9 pounds, on average at 72 weeks, compared to 2.2% weight loss among those who took a placebo. The drug’s weight loss in the study was 9.6% when analyzing all patients regardless of discontinuations.
Eli Lilly’s pill met the trial’s other goals of helping patients lower their hemoglobin A1c, a measure of blood sugar levels. By the end of the study, most patients no longer met the criteria for Type 2 diabetes based on that metric. The rate of side effects and treatment discontinuations in the study, called ATTAIN-2, appeared to be generally consistent with two recent phase three trials on Eli Lilly’s drug.
Eli Lilly said it now has the full clinical trial data package required to file for approvals of the drug for chronic weight management with global regulators. The pharmaceutical giant expects to launch the pill around the world “this time next year,” CEO David Ricks told CNBC in early August.
In an interview, Eli Lilly’s Chief Scientific Officer Daniel Skovronsky, said the pill had “unprecedented efficacy” in patients with obesity and Type 2 diabetes, who typically have a more difficult time losing weight compared to those without diabetes. Skovronsky said he hopes that diabetes patients will be able to use the pill earlier in their disease to slow down its progression.
Existing GLP-1 injections have shown greater weight loss than Eli Lilly’s pill, but having an oral option that offers more than 10% for patients with both obesity and Type 2 diabetes is “actually very good, so that’s positive,” said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital.
But she called it “concerning” that more patients – 10.6% of those on the highest dose – stopped taking the pill due to side effects compared with what has been seen in separate studies on the existing injections, Eli Lilly’s Zepbound and Novo Nordisk‘s Wegovy. Apovian said patients and their prescribers will have to weigh the risks and benefits of the pill and the injections when deciding which to take, including convenience, side effects and efficacy.
The side effects of Eli Lilly’s pill were mainly gastrointestinal, such as nausea and vomiting, and were mild to moderate in severity. An estimated 23.1% of those who took the highest dose experienced vomiting, while 36.4% and 27.4% had nausea and diarrhea, respectively.
Around 20% of patients stopped taking the pill for any reason, which is roughly the same rate as the placebo group. Skovronsky said that reflects a combination of reasons apart from side effects. Those can include patients who wanted to stop participating in a trial because they were able to access another obesity medication, or those who didn’t lose enough weight because they were taking a lower dose of the drug.
But he said most patients stay on the drug, and said “the most important thing here is the scale of the opportunity,” referring to the number of people around the world could benefit from orforglipron. More than 100 million adults in the U.S. alone have obesity, according to Centers for Disease Control and Prevention data.
Apovian said she’s most excited about an oral option entering the market not because of how much weight loss it can promote, but rather its potential to expand access to obesity treatments, especially since a pill is much easier to manufacture than an injection. Apovian hopes Eli Lilly’s pill will be priced lower than injections — which cost roughly $1,000 per month before insurance — and receive broader insurance coverage.
Tuesday’s results are the third set of late-stage data the company has released on orforglipron this year. In April, the pill succeeded in a shorter phase three trial on diabetes patients without obesity.
Earlier this month, the drug also met the goals of a separate study on patients with obesity and not diabetes, but fell short of Wall Street’s expectations. The pill’s weight loss was higher in that trial compared to Tuesday’s data, but “that’s expected,” given the differences in patient populations, said Dr. Jaime Almandoz, medical director of the Weight Wellness Program at UT Southwestern Medical Center.
Overall, some doctors have touted the pill’s weight loss in the trials, and some analysts say it will still be a viable competitor in the space due to factors such as its easier manufacturing and lack of dietary restrictions.
“The convenience and specifically the lack of fasting requirements and water restrictions with orforglipron is likely one of the main differentiators when people think about other oral agents with similar effectiveness for weight change and A1C levels,” said Almandoz.
He said a pill creates additional opportunities for individualized patient care “where there’s more autonomy.”
For example, some people may be hesitant to take injections for weight loss, said Dr. Andrew Krafston, clinical associate professor at the division of metabolism, endocrinology and diabetes at the University of Michigan
“While this is a surmountable barrier for many, oral therapy aligns with traditional medication treatment and may have higher acceptability,” he said, adding that pills are less likely to be in short supply.
Detailed trial data
The trial followed more than 1,600 people, who were randomized to receive three different target doses of Eli Lilly’s pill or a placebo. Patients started at a lower dose of the drug and gradually increased it at four-week intervals to reach their final target dose.
More than 50% of patients on the highest dose of Eli Lilly’s treatment lost at least 10% of their weight in the trial, while 28.4% of those participants lost at least 15%. Across the different groups, the company did not disclose how many patients lost at least 5% of their weight.
Orforglipron “may not be the answer” for patients who are morbidly overweight, said Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart. But he said, “for a lot of people who need to lose a fair amount of weight, losing 10% can make a big diference.”
Orforglipron lowered A1C by an average of 1.3% to 1.8% across different doses at 72 weeks, from a starting level of 8.1%. Around 75% of participants taking the highest dose achieved an A1C of 6.5% or less, which is at or below what the American Diabetes Association defines as diabetes.
Eli Lilly’s pill also improved key cardiovascular risk factors.
“We now have study after study with GLP-1 agonists showing that they reduce very important outcomes, which is what I do every day as a preventive cardiologist,” Weintraub said. “I try my very best to prevent them from having heart attack, stroke and death.”
Eli Lilly’s pill works in a similar way to Wegovy, Ozempic and Novo Nordisk’s diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person’s appetite and regulate blood sugar. Novo Nordisk is also seeking approval of an oral version of Wegovy, which could come by year-end.
But unlike those three medications, Eli Lilly’s pill is not a peptide medication. That means it is absorbed more easily by the body and does not require dietary restrictions like Rybelsus or oral Wegovy does.
Business
Want To Buy A House In Karnataka? Know About The ‘Namma Mane’ Scheme With Affordable Housing & Subsidies
Last Updated:
The programme aims to make land ownership more accessible for eligible residents while supporting the government’s wider goal of providing housing for all.

Under the ‘Namma Mane’ housing scheme 50,000 residential plots will be distributed at concessional rates over the next two years.
What if owning a home became a little more achievable? In the latest Karnataka Budget, the state government has announced a series of housing initiatives aimed at expanding access to affordable homes and residential plots. From the ‘Namma Mane’ scheme offering concessional sites to increased subsidies for beneficiaries and plans for a massive sports complex in Anekal, the announcements signal a renewed push towards housing development across the state.
The Karnataka government has unveiled several housing and infrastructure initiatives in the latest state budget, including the distribution of thousands of residential plots and the construction of a large sports complex in Bengaluru’s Anekal taluk. The announcements are part of broader efforts to expand housing access and improve public infrastructure across the state.
Karnataka Budget Housing Scheme: Key Benefits
One of the key proposals is the introduction of the ‘Namma Mane’ housing scheme, under which 50,000 residential plots will be distributed at concessional rates over the next two years. The programme aims to make land ownership more accessible for eligible residents while supporting the government’s wider goal of providing housing for all.
The Housing Department has also set a new target of sanctioning one lakh houses under various housing schemes in the state. These houses will be approved based on the Beneficiary Led Construction (BLC) model, which allows eligible beneficiaries to construct their own homes with financial support from the government.
As part of this initiative, the government has increased the subsidy amount provided under housing schemes. For beneficiaries in the general category, the subsidy has been raised from Rs 1.20 lakh to Rs 2 lakh. Meanwhile, beneficiaries from Scheduled Castes and Scheduled Tribes will receive increased assistance, with the subsidy rising from Rs 2 lakh to Rs 3 lakh.
The budget also introduces a change in the process used to select beneficiaries for state housing schemes. Instead of the traditional manual lottery system, selections will now be conducted through an online lottery in Gram Sabhas. The move is expected to improve transparency and streamline the allocation process.
In addition to housing initiatives, the Karnataka Housing Board has announced plans to develop a major sports facility in Anekal taluk of Bengaluru Urban district. The project, titled ‘KHB Surya Krida Grama’, will include the construction of an 80,000-seat cricket stadium designed to host international sporting events.
Meanwhile, the Karnataka Slum Development Board is continuing the implementation of housing projects under the Pradhan Mantri Awas Yojana (AHP). A total of 1.29 lakh houses are being constructed under the scheme, with 79,134 homes dedicated for the year 2025–26. The state government has allocated an additional grant of Rs 1,136 crore to support the project, providing permanent housing to many slum residents.
Since the Congress government came to power, Rs 7,328 crore has been spent on various housing schemes. So far, 4,19,454 houses have been completed and handed over to beneficiaries. The government has set a target to complete three lakh houses during the current year.
Authorities have also stated that steps will be taken to complete the 4.90 lakh houses sanctioned by the previous government, even though they were approved without grants.
March 07, 2026, 10:51 IST
Stay Ahead, Read Faster
Scan the QR code to download the News18 app and enjoy a seamless news experience anytime, anywhere.

Business
Emirates resumes some Dubai flights – what’s the latest on travel to UK?
New flights to the UK from the Middle East follow days of widespread air travel disruption which had left Britons stranded.
Source link
Business
‘Indians been good actors’: Why US ‘agreed to let’ India resume buying Russian oil temporarily – The Times of India
The United States has given “permission” to India to buy Russian oil already stranded at sea issuing a temporary waiver aimed at stabilising global oil supplies amid disruptions caused by the escalating conflict in West Asia.US President Donald Trump’s aide Scott Bessent referred to India as a “very good actor” for previously complying with Washington’s request to halt purchases of sanctioned Russian oil and said the temporary measure would help ease supply pressures in the global market.
The move comes a day after Washington issued a 30-day waiver permitting the sale of Russian crude currently stranded at sea to continue to India.
US cites temporary supply concerns
Speaking to Fox Business, US treasury secretary Bessent said the decision was intended to ease short-term supply constraints during the ongoing crisis.“The world is very well supplied in oil. The Treasury (Department) agreed to let our allies in India start buying Russian oil that was already on the water,” Bessent said.“The Indians had been very good actors. We had asked them to stop buying sanctioned Russian oil this fall. They did. They were going to substitute it with US oil,” he said.“But to ease the temporary gap of oil around the world, we have given them permission to accept the Russian oil. We may unsanction other Russian oil,” he added.Bessent also noted that a large volume of sanctioned crude remains stranded at sea stating that, “There are hundreds of millions of sanctioned barrels of sanctioned crude on the water,” he said, adding that “by unsanctioning them, Treasury can create supply.”“And we are looking at that. We are going to keep a cadence of announcing measures to bring relief to the market during this conflict,” he added.

‘Short term measures to help keep oil prices down’
Other officials in the Trump administration have also confirmed that Washington has “permitted” India to buy Russian crude that is already loaded on ships.Earlier, US energy secretary Chris Wright said the step was intended to quickly move existing oil supplies into the market.“We have implemented short term measures to help keep oil prices down. We are allowing our friends in India to take oil that is already on ships, refine it, and move those barrels into the market quickly. A practical way to get supply flowing and ease pressure,” Wright said in a post on X.In an interview with ABC News Live, Wright emphasised that the measure was temporary.“But as oil gets bid up a little bit because of those constraints coming out of the Strait of Hormuz, we’re taking a short-term action to say all this floating Russian oil storage that’s around Southern Asia, it’s China just backed up, China does not treat their suppliers well, so there’s a bunch of floating barrels just sitting there,” he said.“We’ve reached out to our friends in India and said, ‘Buy that oil. Bring it into your refineries’. That pulls stored oil immediately into Indian refineries and releases the pressure on other refineries around the world to buy oil that they’re no longer competing with the Indians for in that marketplace,” Wright added.“So we have a number of measures like that that are short-term and temporary. This is no change in policy towards Russia. This is a very brief change in policy just to keep oil prices down a little bit better than we could otherwise,” he further noted.
Waiver amid Strait of Hormuz tensions
The US Treasury earlier issued an order granting a 30-day licence allowing delivery and sale of Russian crude and petroleum products to India. The decision comes as shipping routes through the strategically important Strait of Hormuz face disruptions due to the ongoing conflict in the region.“President Trump’s energy agenda has resulted in oil and gas production reaching the highest levels ever recorded. To enable oil to keep flowing into the global market, the Treasury Department is issuing a temporary 30-day waiver to allow Indian refiners to purchase Russian oil,” Bessent said earlier.He stressed that the step was a limited measure and would not significantly benefit Moscow.“This deliberately short-term measure will not provide significant financial benefit to the Russian government, as it only authorises transactions involving oil already stranded at sea,” he said.“India is an essential partner of the United States, and we fully anticipate that New Delhi will ramp up purchases of US oil. This stop-gap measure will alleviate pressure caused by Iran’s attempt to take global energy hostage,” he added.
India’s oil supply position
The move comes months after the Trump administration imposed 25% punitive tariffs on India over its purchases of Russian oil, arguing that such imports were helping finance Moscow’s war against Ukraine.However, the tariffs were later lifted after the two countries agreed on a framework for an interim trade agreement and India committed to reducing imports from Russia while increasing purchases of American energy.India currently imports nearly 5.5–5.6 million barrels of crude oil per day, accounting for about 90% of its domestic consumption. Officials say the country’s energy position remains comfortable despite the regional tensions.Around 15 million barrels of crude are currently on tankers in the Arabian Sea and the Bay of Bengal, while vessels carrying another seven million barrels are waiting near Singapore. Additional tankers in the Mediterranean and the Suez Canal are also heading towards Indian ports and could arrive within a week.According to data from Kpler, India imported slightly over 1 million barrels per day of Russian crude in February, compared with 1.1 million bpd in January and 1.2 million bpd in December.Before the Ukraine war in 2022, Russian crude accounted for just 0.2% of India’s imports, but purchases increased sharply after Moscow began offering deep discounts.
-
Business1 week agoAttock Cement’s acquisition approved | The Express Tribune
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
-
Business1 week agoIndia Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Sports1 week agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’
-
Sports1 week agoSri Lanka’s Shanaka says constant criticism has affected players’ mental health
-
Entertainment1 week agoBobby J. Brown, “The Wire” and “Law & Order: SUV” actor, dies of smoke inhalation after reported fire
-
Fashion1 week agoSouth Korea’s Misto Holdings completes planned leadership transition
